Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that important new data from clinical trials of several investigational and approved cancer medicines will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 to June 4, 2013, in Chicago. At the meeting, Genentech medicines will be highlighted in more than 275 abstracts, of which approximately one third were chosen for oral presentations. The collection of data at ASCO represents Genentechs breadth of research and includes:

We need treatments that attack cancer cells in a variety of ways to continue to make a difference to the lives of people facing this disease, said Hal Barron, M.D., chief medical officer and head, Global Product Development. From harnessing a persons immune system to delivering chemotherapy directly to a cancer cell, we believe the new data from our pipeline presented at ASCO have the potential to markedly change how cancer is treated.

Full session details of the 2013 Annual Meeting can be found through the ASCO iPlanner: https://www.iplanner.asco.org/am2013.

Key Genentech Meeting Highlights Include:

GA101: Unique Investigational Anti-CD20 Antibody

The Phase III study CLL11, which is being conducted in close collaboration with the German CLL Study Group (GCLLSG), compared the combination of either GA101 or Rituxan (rituximab) and standard chemotherapy (chlorambucil) to chlorambucil alone. The study included people with previously untreated chronic lymphocytic leukemia (CLL), one of the most common forms of blood cancer, who were elderly and are often not able to tolerate existing standard options for CLL.

GA101 (RG7159, obinutuzumab) is the first investigational glycoengineered Type II anti-CD20 medicine, which means specific sugar molecules in GA101 were modified (using GlycoMAb technology) to change its interaction with the bodys immune cells with the goal of helping the immune system remove cancer cells from the body. In addition, as a Type II anti-CD20 antibody, GA101 binds to CD20 with the aim of killing cancerous cells directly.

Anti-PDL1: Immunotherapy

Anti-PDL1 antibody MPDL3280A (RG7446) is an investigational medicine designed to make cancer cells more vulnerable to the bodys own immune system by interfering with a protein called PD-L1. Several early stage studies of MPDL3280A in various cancer types will be presented, including data on potential biomarkers. These data will also be highlighted as part of ASCOs official press program on May 15, 2013.

See more here:
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO